Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance

The development of inhibitors for the tyrosine anaplastic lymphoma kinase (ALK) has advanced rapidly, driven by biology and medicinal chemistry. The first generation ALK inhibitor crizotinib was granted US FDA approval with only four years of preclinical and clinical testing. Although this drug offe...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Zilan, Wang, Meining, Zhang, Ao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629211/
https://www.ncbi.nlm.nih.gov/pubmed/26579422
http://dx.doi.org/10.1016/j.apsb.2014.12.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629211/
https://www.ncbi.nlm.nih.gov/pubmed/26579422
http://dx.doi.org/10.1016/j.apsb.2014.12.007

Ejemplares similares